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Abstract: Cholinergic deficits are an early and functionally significant manifestation of 
Alzheimer’s disease (AD). These deficits contribute to impairment of hippocampally mediated 
information processing, including declarative memory impairments and abnormal auditory 
sensory gating. A functional imaging technique that facilitates identification of changes in 
cholinergically dependent hippocampal information processing would be of considerable use 
in the study and clinical evaluation of persons with this condition. Techniques that interrogate 
hippocampal function passively, ie, in a manner requiring no cognitive effort or novel task learning 
during the neuroimaging procedure, would also be especially useful in this cognitively impaired 
population. The functional magnetic resonance imaging sensory gating paradigm developed at 
the University of Colorado, CO, USA, is a functional neuroimaging technique that possesses 
both of these characteristics. We developed a demonstration project using this paradigm in 
which we passively interrogated hippocampal function in two subjects with probable AD of 
mild severity. Imaging data were quick and easy in these subjects and served usefully as an 
initial demonstration of the feasibility of using this neuroimaging method in this population. 
Preliminary analyses of the data obtained from these subjects identified abnormal blood oxygen 
level-dependent responses when compared with four healthy comparators, and the pattern of 
these responses was consistent with impaired function of the auditory sensory gating network. 
The strengths and limitations of this neuroimaging paradigm and the additional issues that 
require investigation in order to continue its development into a research and clinical technique 
for use in this population are discussed.
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Introduction
Early identification of Alzheimer’s disease (AD) is needed to facilitate timely treatment 
delivery and to improve quality of life for affected patients and their families.1 
Cholinergic deficit is present early in the course of AD2,3 and is a likely contributor 
to the earliest clinical manifestations of this illness, including declarative memory 
impairments2,3 and disturbances of preattentive information filtering (ie, impaired 
auditory sensory gating).4,5 The latter of these impairments reflects cholinergic deficit-
related abnormal hippocampal physiology, disturbances of which are amenable to 
identification using the functional magnetic resonance imaging (fMRI) auditory sen-
sory gating paradigm. First described by Tregellas et al,6 this brief and behaviorally 
passive fMRI paradigm interrogates the functional integrity of the cholinergically 
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auditory sensory gating.6,7 Diminished availability or action 
of acetylcholine to the hippocampus impairs the ability of this 
structure to perform its inhibitory (ie, information filtering) 
function in this network. This cholinergic deficit-induced 
failure of inhibitory function is the putative neurobiological 
basis for the increased blood oxygen level-dependent (BOLD) 
signal (ie, excessive activation) in the hippocampus that is 
evoked by the auditory sensory gating paradigm.6
The fMRI auditory sensory gating paradigm therefore might 
be a viable method by which to identify AD-induced, cholin-
ergic deficit-mediated, hippocampal dysfunction. The primary 
aim of this proof-of-concept study was to assess the feasibility 
of evaluating auditory sensory gating among persons with AD 
with this fMRI paradigm. A secondary and exploratory aim 
was a preliminary test of the hypothesis that the fMRI auditory 
sensory gating paradigm evokes greater activation (ie, identifies 
failed inhibitory function) of the hippocampus in AD subjects 
when compared with healthy comparison subjects.
Materials and methods
This study was approved by the Colorado Multiple 
Institutional Review Board. Only decisionally capable 
subjects with AD were eligible for study participation, and 
informed consent was obtained from all study participants.
Subjects
Subjects were included if clinical interview, neuropsychiatric 
examination, and medical records review established a diagnosis 
of probable AD by the National Institute for Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease 
and Related Disorder Association (NINDS-ADRDA) criteria.8 
Subjects were assessed cognitively using the Mini-Mental Status 
Examination (MMSE),9 Frontal Assessment Battery (FAB),10 
and Alzheimer’s Disease Assessment Scale-Cognitive Subscale 
(ADAS-Cog).11 MMSE z-scores12 # −2 were required for a diag-
nosis of probable AD. Subjects with focal neurological deficits, 
parkinsonism, a Hachinski Ischemic Scale13 score .4, neurode-
velopmental, substance use, and psychiatric disorders and those 
taking cognitively impairing medications were excluded. Data 
from healthy adults studied previously in the laboratory of one 
of the investigators (JRT) were used to develop a convenience 
comparison sample for the MRI analyses.
Magnetic resonance imaging
Studies were performed with a 3T GE MRI system (GE Health-
care, Milwaukee, WI, USA) using a standard quadrature 
head coil. Imaging parameters were followed as described by 
Tregellas et al,6 as was administration of the fMRI sensory 
gating paradigm. Briefly, subjects were administered a hear-
ing test in the scanner to set the task volume at 50 dB above 
the hearing threshold. Click stimuli consisted of ‘broadband 
chirps’, 10 msec in duration, designed to elicit robust cortical 
responses. The paradigm used a clustered volume acquisition 
approach to allow a 6-sec silent period following scanner 
noise for neuronal inhibitory circuitry to reset and allow 
auditory stimuli to be presented during silence. During the 
12-sec period between scanner noise, subjects heard 4 sec of 
1) silence, 2) one click, or 3) multiple (‘repeated’) clicks with 
a 0.5-sec interclick interval. Auditory stimuli were centered 
at 8 sec after scanner noise ended. The following volume 
was acquired 4–6 sec after auditory   stimulation to capture 
peak hemodynamic response. Two stimulus presentations 
comprised one block. Twenty-eight-sec blocks of ‘silence’, 
‘one click’, or ‘repeated clicks’ were presented to the subjects 
over three runs, totaling 21 min. Five blocks of each stimulus 
type were randomly distributed throughout each run. Between 
runs, brief conversations were held with subjects to ensure 
that they were awake and responsive. The contrast ‘repeated 
clicks–one click’ was the measure of auditory sensory gating. 
This subtraction removes most of the effects of overall audi-
tory responsiveness, which was measured separately in the 
contrast ‘one click–silence.’ Multiple clicks, rather than a 
click pair, were used to maximize sensitivity to the difference 
in BOLD response between the two stimulus conditions.
The fMRI analyses were performed using Statistical Para-
metric Mapping software version 5 (SPM5; Wellcome Trust 
Centre for Neuroimaging, London, UK; http://www.fil.ion.
ucl.ac.uk/spm/software/spm5/) and used a region of interest 
(ROI) approach. Data from each subject were realigned to the 
first volume, normalized to the Montreal Neurological Insti-
tute gray-matter template, using a gray-matter-segmented IR-
EPI as an intermediate to improve registration, and smoothed 
with 8-mm FWHM Gaussian kernel. Data were modeled with 
an HRF-convolved boxcar function, using the general linear 
model in SPM5. A 128-sec high-pass filter was applied to 
remove low-frequency fluctuation in the BOLD signal. A 
random effects analysis was used to evaluate hippocampal 
response. The ROI was an 8-mm sphere centered at x = −24, 
y = −18, and z = −15, the hippocampal location that showed 
maximal group differences in a previous study using the 
sensory gating task.6 Data within the ROI were small volume 
corrected at a family-wise error rate of P , 0.05.
Results
Two individuals satisfying NINDS-ADRDA criteria for 
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paradigm. The first was a 71-year-old, right-handed man with 
a 6-year history of probable AD who was on stable treatment 
with donepezil 10 mg daily and memantine 10 mg twice daily. 
His MMSE was 24/30 (z = −2.5), FAB was 11/18, and ADAS-
Cog was 22/70. The second was a 78-year-old, right-handed 
woman with a 7-year history of probable AD who was on 
stable treatment with donepezil 10 mg daily and memantine 
5 mg twice daily. Her MMSE was 22/30 (z = −3.8), FAB was 
11/18, and ADAS-Cog was 34/70. Clinical examination and 
assessment of functional status (obtained by caregiver inter-
view) classified AD severity in both subjects as mild. Both 
subjects tolerated the imaging procedure easily, remained 
alert (per visual monitoring of subjects during scanning by 
our research assistant), and yielded fMRI data of quality 
sufficient to subject those data to analyses.
The convenience comparison sample consisted of four 
healthy subjects drawn from prior studies in our laboratory. 
The mean age of this group was 52.0 ± 2.2 years. As the 
mean age of the AD group was significantly older (74.5 ± 4.9; 
P , 0.001), age was used as a covariate in the fMRI data 
analyses.
Consistent with our a priori hypothesis, subjects with 
AD demonstrated abnormal activation of the hippocampus 
(t = 3.61; see Figure 1). Single-subject BOLD responses at the 
hippocampal local maxima, expressed as percent signal change 
relative to the global mean, are presented in Figure 2.
Discussion
The fMRI auditory sensory gating paradigm appears   
to be a feasible method of evaluating the preattentive 
information-filtering function of the cholinergically 
dependent hippocampally mediated auditory sensory gating 
network among persons with AD. In respect of its potential 
practicality, the fMRI auditory sensory gating paradigm 
assesses hippocampal function in a single, relatively brief, 
MR imaging session; such brevity is an important feature 
for the practical application of fMRI assessments in the AD 
population. Additionally, it assesses hippocampal function 
using a passive protocol; the only in-scanner behavioral 
requirement of persons with AD is to remain awake. As 
dementia due to AD entails difficulty learning new informa-
tion and executing complex tasks, imaging paradigms that 
interrogate hippocampal function by passive means, like ours 
and that of others,14 offer potential practical advantages over 
those that require subjects to learn and perform novel in-
scanner cognitive tasks.15–18 The unimodal imaging approach 
employed here also offers potential feasibility advantages 
over others that, although robust, may be relatively more 
time and resource intensive in respect of data acquisition 
and analyses.14,19,20 Additionally, the emphasis on hippocam-
pal function rather than structure is an important feature 
of this approach, given the variable relationship between 
hippocampal structure and clinical symptoms in the early 
stages of AD.3,21–24
The preliminary analysis of the fMRI data obtained 
during this demonstration project identified greater 
BOLD signal in the hippocampus of the two AD subjects 
when compared with healthy comparison subjects, even 
after correcting for the between-group age difference. 
This observation is consistent with our predicted effects 
of AD neuropathology on the neurobiology of auditory 
sensory gating. The single-subject BOLD responses at the 
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Figure 1 Sagittal (left) and coronal (right) views of BOLD response during the fMRI auditory sensory gating paradigm (contrast: AD subjects . healthy comparison subjects). 
These responses are overlaid on an average anatomical image constructed using data acquired from healthy comparison subjects and employ radiological convention 
(right on left).
Abbreviations: BOLD, blood oxygen level-dependent; fMRI, functional magnetic resonance imaging; AD, Alzheimer’s disease.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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hippocampal local maxima identified in the between-group 
comparison presented in Figure 2 are also noteworthy in 
that there is no overlap between the AD and healthy com-
parison subjects. As a proof-of-concept exercise, these 
data are encouraging of the possibility that, with further 
development, BOLD responses during the fMRI auditory 
sensory gating paradigm might contribute usefully to the 
research and/or clinical assessments of persons with late-
life cognitive impairments.
The preliminary nature of this study, however, necessitates 
cautious interpretation of these findings and suggestions. Rep-
lication of this work in a larger sample of subjects with AD 
and age- and gender-matched healthy comparison subjects is 
required to evaluate the usefulness of this fMRI protocol as a 
method of identifying AD-induced hippocampal dysfunction. 
Given the preponderance of women affected by this condi-
tion and previously observed sexual dimorphism in cerebral 
responses to fMRI-related auditory stressors,18 the possibil-
ity of sexual dimorphism in BOLD responses in the fMRI 
auditory sensory gating paradigm requires consideration and 
investigation. Additionally, studies are needed to determine 
whether this paradigm distinguishes individuals with AD from 
individuals with memory impairment due to other common 
late-life neuropsychiatric conditions, especially dementias 
caused by other forms of neurodegeneration and/or cerebro-
vascular disease.
It is also important to note that sensory gating impairments 
are not specific to AD but are instead features of a wide range 
of neuropsychiatric conditions, most notably schizophrenia6,25 
and traumatic brain injury.7 A common theme across these 
conditions is cholinergic dysfunction. Loss of ventral forebrain 
neurons and their cortical efferents in AD2,3 and traumatic brain 
injury26–28 and (maladaptive) mutation of alpha-7 nicotinic 
cholinergic receptors in   schizophrenia25 are the putative bases 
for auditory sensory gating impairments in these conditions. It 
is possible that the fMRI auditory sensory gating paradigm will 
be understood most usefully as an assessment of the integrity 
of this system independent of clinical diagnosis. If so, then it 
may not be a marker of early AD per se but instead a marker 
of any condition in which cholinergic dysfunction occurs, 
whether by loss of cholinergic neurons, injury to their axons, 
or altered responsiveness to acetylcholine at their cortical 
targets. Increased BOLD responses observed in older patients 
during the fMRI auditory sensory gating paradigm might 
only narrow the range of potential etiologic explanations for 
cognitive complaints to those conditions in which cholinergic 
dysfunction figures prominently (ie, AD, amnestic mild cogni-
tive impairment, diffuse Lewy body disease, traumatic brain 
injury, and, possibly, cerebrovascular disease).29 If such studies 
demonstrate that this method is useful for any of these purposes 
at the group and single-patient levels, then the timing and 
economic implications of its introduction into the diagnostic 
evaluation of persons with suspected AD will also need to be 
considered.
For the present, this initial ‘proof-of-concept’ demonstra-
tion is encouraging of the potential usefulness of the fMRI 
auditory sensory gating paradigm in AD research. The present 
findings suggest that further development and investigation 
of this neuroimaging technique are warranted.
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